Tigecycline
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Infections
Conditions
Staphylococcal Infections
Trial Timeline
Jan 1, 2007 → May 1, 2008
NCT ID
NCT00419991About Tigecycline
Tigecycline is a approved stage product being developed by Pfizer for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00419991. Target conditions include Staphylococcal Infections.
What happened to similar drugs?
3 of 4 similar drugs in Staphylococcal Infections were approved
Approved (3) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01560143 | Approved | Completed |
| NCT01401023 | Pre-clinical | Completed |
| NCT01072539 | Pre-clinical | Completed |
| NCT00827541 | Pre-clinical | Completed |
| NCT00575094 | Phase 3 | Completed |
| NCT00419991 | Approved | Completed |
| NCT00406237 | Phase 1 | Completed |
| NCT00488488 | Pre-clinical | Completed |
| NCT00376324 | Phase 1 | Completed |
| NCT00488306 | Approved | Completed |
| NCT00488761 | Approved | Completed |
| NCT00136201 | Phase 3 | Completed |
| NCT00205816 | Phase 3 | Completed |
| NCT00079989 | Phase 3 | Completed |
| NCT00079885 | Phase 3 | Completed |
| NCT00079976 | Phase 3 | Completed |
| NCT00081744 | Phase 3 | Completed |
| NCT00600600 | Phase 2 | Completed |
Competing Products
20 competing products in Staphylococcal Infections